TABLE 3.
Relevance to the false-positive outcome between the treatment of the case and control groups.
| Variables | Case (n = 20) | Control (n = 80) | Crude OR | 95% CI | p |
|---|---|---|---|---|---|
| Vasopressor agents | 12 (60.0%) | 34 (42.5%) | 2.03 | 0.748–5.508 | 0.165 |
| Anesthetic | 7 (35.0%) | 35 (43.8%) | 0.69 | 0.250–1.919 | 0.480 |
| Benzodiazepine | 18 (90.0%) | 58 (72.5%) | 3.41 | 0.731–15.941 | 0.118 |
| Neuromuscular blocker | 11 (55.0%) | 33 (41.2%) | 1.741 | 0.649–4.671 | 0.271 |
| Opioid | 12 (60.0%) | 60 (75.0%) | 0.50 | 0.1779–1.397 | 0.186 |
| Soybean contained injection | 7 (35.0%) | 36 (45.0%) | 0.658 | 0.238–1.823 | 0.421 |
| Penicillin | 13 (65.0%) | 61 (76.2%) | 0.578 | 0.202–1.658 | 0.308 |
| β-Lactamase inhibitor | 13 (65.0%) | 62 (77.5%) | 0.539 | 0.187–1.553 | 0.253 |
| Amoxicillin/clavulanate acid | 0 (0.0%) | 8 (10.0%) | - | 0.999 | |
| Ampicillin/sulbactam | 2 (10.0%) | 13 (16.2%) | 0.573 | 0.118–2.772 | 0.488 |
| Cefoperazone/sulbactam | 1 (5.0%) | 8 (10.0%) | 0.474 | 0.056–4.024 | 0.494 |
| Piperacillin/tazobactam | 12 (60.0%) | 52 (65.0%) | 0.808 | 0.295–2.208 | 0.677 |
| Cephalosporin | 11 (55.0%) | 44 (55.0%) | 1.000 | 0.373–2.678 | 1.000 |
| Carbapenem | 8 (40.0%) | 37 (46.2%) | 0.775 | 0.286–2.099 | 0.616 |
| Lincosamide | 1 (5.0%) | 1 (1.2%) | 4.158 | 0.249–69.526 | 0.321 |
| Glycopeptide | 9 (45.0%) | 37 (46.2%) | 0.951 | 0.355–2.545 | 0.920 |
| Aminoglycoside | 2 (10.0%) | 6 (7.5%) | 1.370 | 0.255–7.361 | 0.713 |
| Triazole | 6 (30.0%) | 21 (26.2%) | 1.204 | 0.410–3.540 | 0.736 |
| Metronidazole | 1 (5.0%) | 3 (3.8%) | 1.351 | 0.133–13.721 | 0.799 |
| Colistin | 6 (30.0%) | 1 (1.2%) | 33.857 | 3.782–303.116 | 0.002 a |
a
p < 0.05, achieved statistically significant difference.